SCHEMBL12378540

SCHEMBL12378540

Cc1ccc(S(=O)(=O)OCCN(C)S(C)(=O)=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
CA1 P00915 1/20 0.40
STAT3 P40763 1/20 0.39
CA2 P00918 1/20 0.39
MAPT P10636 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
CYP2D6 P10635 2/20 0.38
CYP1A2 P05177 1/20 0.38
GAA P10253 1/20 0.38
PTGS2 P35354 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
C5AR1 P21730 1/20 0.37
AGER Q15109 1/20 0.37
VDR P11473 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336434 0.87 MAPT (0.46) CA12CA9MAPTMCOLN3C5AR1
SCHEMBL3614979 0.85 CA12 (0.49) ALDH1A1CA12CA9CA1STAT3
SCHEMBL13817382 0.85 CYP2D6 (0.43) ALDH1A1CA12CA9CA1STAT3
Hydrochloric Acid SCHEMBL28936935 0.83 ALOX15 (0.50) ALDH1A1CA12CA9CA1STAT3
SCHEMBL28721741 0.81 CA12 (0.45) ALDH1A1CA12CA9CA1STAT3
SCHEMBL241884 0.80 CA1 (0.52) ALDH1A1CA12CA9CA1STAT3
SCHEMBL20438627 0.79 CA12 (0.44) ALDH1A1CA12CA9CA1STAT3
SCHEMBL995109 0.79 CA12 (0.54) ALDH1A1CA12CA9CA1STAT3
SCHEMBL2335489 0.79 GLA (0.50) CA12CA9CA1MAPTMCOLN3
SCHEMBL11094115 0.78 CA1 (0.48) ALDH1A1CA12CA9CA1STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US disclosed
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US disclosed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US disclosed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
WO-2007136714-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058315-A1 Integrase inhibitors TYMP, DNTT, PAICS ALDH1A1 2040/4885CA12 4732/4885CA9 4348/4885
US-20090306054-A1 INTEGRASE INHIBITORS TYMP, POLR2E, CCNI ALDH1A1 1220/4885CA12 4724/4885CA9 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.